Recession continues to impact health care
This article was originally published in The Gray Sheet
Executive Summary
Medicaid expenditures grew at a faster pace than Medicare spending in 2009, at 9.9% and 8.1% respectively, according to CMS projections released Feb. 4. The jump in Medicaid spending was based largely on increased enrollment due to the recession, CMS said. Overall U.S. health care expenditures are expected to have grown 5.7% in 2009 to $2.5 trillion. The agency expects the recession contributed to lower demand for services with significant out-of-pocket expenses, and projects the growth in out-of-pocket spending slowed from 2.8% in 2008 to 2.1% in the U.S. in 2009. For the 10-year period from 2009-2019, CMS projects average annual spending growth overall will be 6.1% for hospitals and 5.9% for physician and clinical services. Last month, CMS reported that the growth of U.S. health care expenditures had slowed in 2008, the last full year for which data is available (1"The Gray Sheet" Jan. 11, 2010). CMS projects that by 2019, national health expenditures will reach $4.5 trillion, or 19.3% of the gross domestic product, with government health care spending growing at a faster rate than private spending
You may also be interested in...
Health Care Not Recession-Proof, National Spending Data Indicates
The current recession has had a more immediate impact on U.S. health care spending than seen in other recent economic downturns, according to the lead author of a Jan. 5 CMS report on 2008 national health expenditures
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.